Oncology From promise to practice: What must happen next for genetic ... The systems needed to deliver GBT testing consistently across the NHS are still evolving to keep pace with these scientific advances.
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Oncology From preclinical toxicology to clinical safety: The path for... Successfully navigating the process for drugs with a higher risk-benefit ratio requires a tailored non-clinical programme design.
Oncology Advancing the case for cell and gene therapies After the Advanced Therapies Congress, Europe, pharmaphorum spoke with Resolution Therapeutics' Lara Campana and Vianautis' Dr Sam Barker.
Oncology Radiopharmaceutical development is accelerating. Preclinical... Radiopharmaceuticals are rapidly becoming one of the most dynamic areas of oncology drug development.
Oncology Hernexeos and what’s next, with Vicky Brown At Reuters Pharma USA this week, Boehringer Ingelheim's Vicky Brown spoke with us about the company's recent US approval for Hernexeos in NSCLC.
News Parexel buys Vitrana to boost patient safety toolkit Contract research organisation Parexel has bought Vitrana and its AI-powered pharmacovigilance platform for an undisclosed sum.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.